RxDoctor Payments Data

Adam Luber, MD

Dermatology · Phoenix, AZNPI 1396155867

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 56.5% of the total. Reporting peaked in 2024 at $2,789 and has fallen 78.0% since, to $614 in 2025.

$4,065in general payments, 2019–2025

Across 57 payments — averaging $71.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • AbbVie$428
  • Sanofi$257
  • Pfizer$156
  • Lilly USA, LLC$121
  • Sun Pharmaceutical Industries Inc.$116
  • plus $690 from 13 others
$238,466in research payments, 2019–2025

Across 197 payments — averaging $1210.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$183K
  • AbbVie$46K
  • Sanofi US Services Inc.$5K
  • Amgen$5K

What the payments were for

  • Consulting fees$2,13553%
  • Food & beverage$1,70142%
  • Education$2296%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,065 in reported general payments places this provider in the 60th percentile of 305 dermatology providers in Arizona.

See all dermatology providers in Arizona

Medicare billing

Part B allowed, 2024
$681,106
Medicare patients
2,135
Services billed
8,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$106,337
Fluorouracil202$13,871
Clobetasol Propionate89$4,673
Ketoconazole267$4,005
Triamcinolone Acetonide225$1,800
Clindamycin Phosphate37$1,316
ValacyclovirValacyclovir Hcl36$1,213
Metronidazole15$1,195
Azelaic Acid12$970
Ciclopirox15$751
Ammonium Lactate27$657
Hydrocortisone92$492
Doxycycline Monohydrate32$419
Imiquimod14$407
Mupirocin49$327

Paid to pharmacies, not to this prescriber.

Other dermatology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →